结直肠癌筛查策略的微模拟模型研究:FIT、乙状结肠镜与结肠镜
该微模拟模型研究基于挪威50-79岁人群,比较了每两年或每年FIT、单次乙状结肠镜或结肠镜筛查与不筛查相比,在15年随访内对结直肠癌死亡率和发病率的影响。结果显示所有筛查策略均可能相似程度降低死亡率,结肠镜和乙状结肠镜还可降低发病率,FIT的发病率降低幅度较小;危害罕见且各策略相似,但证据确定性低。
要点
- 所有筛查策略在15年内均可相似程度降低结直肠癌死亡率。
- 结肠镜和乙状结肠镜可降低结直肠癌发病率,FIT发病率降低较小。
- 筛查危害罕见且各策略相似,危害随年龄增长而增加。
核心结论
- 在15年随访期内,所有筛查策略可能相似程度降低结直肠癌死亡率。
- 结肠镜和乙状结肠镜可能降低结直肠癌发病率,FIT的发病率降低幅度较小。
- 所有筛查策略的危害均罕见且程度相似。
研究设计与样本
- 采用MISCAN-Colon微模拟模型研究,由平行指南委员会(BMJ Rapid Recommendations)定义时间框架和筛查干预措施。
- 人群为挪威50-79岁男性和女性,15年结直肠癌风险为1-7%。
- 比较四种筛查策略与不筛查:每两年或每年FIT、单次乙状结肠镜或结肠镜,假设100%依从性。
- 主要结局为15年随访内的结直肠癌死亡率、发病率、负担和危害,证据确定性采用GRADE方法评估。
主要发现
- 在15年随访中,对50-79岁、结直肠癌风险3%的人群,每年FIT或单次结肠镜筛查使结直肠癌死亡率每1000人减少6例。
- 单次乙状结肠镜和每两年FIT使结直肠癌死亡率每1000人减少5例。
- 结肠镜、乙状结肠镜和每年FIT分别使结直肠癌发病率每1000人减少10例、8例和4例。
- 每两年FIT的估计发病率降低为每1000人减少1例。
- 严重危害估计在每1000人3例(每两年FIT)至5例(结肠镜)之间,危害随年龄增长而增加。
关键数值与推荐
- 筛查的绝对获益随结直肠癌基线风险增加而增加,而危害受基线风险影响较小。
- 结果对指南小组定义的设置敏感。
- 由于模型假设的不确定性,对所有估计值应用GRADE评级为低确定性证据。
临床怎么用
- 全科医生可向50-79岁患者说明所有筛查策略均可能相似程度降低结直肠癌死亡率。
- 结肠镜和乙状结肠镜可额外降低结直肠癌发病率,FIT的发病率降低幅度较小。
- 筛查危害罕见且各策略相似,但老年人危害增加,需结合基线风险个体化讨论。
- 因证据确定性低,决策时应充分告知患者模型假设的不确定性。
局限性
- 证据确定性低,因模型假设存在不确定性。
- 结果对指南小组定义的设置敏感。
- 模型假设100%依从性,可能高估实际筛查效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate benefits and harms of different colorectal cancer screening strategies, stratified by (baseline) 15-year colorectal cancer risk. DESIGN: Microsimulation modelling study using MIcrosimulation SCreening ANalysis-Colon (MISCAN-Colon). SETTING: A parallel guideline committee (BMJ Rapid Recommendations) defined the time frame and screening interventions, including selection of outcome measures. POPULATION: Norwegian men and women aged 50-79 years with varying 15-year colorectal cancer risk (1-7%). COMPARISONS: Four screening strategies were compared with no screening: biennial or annual faecal immunochemical test (FIT) or single sigmoidoscopy or colonoscopy at 100% adherence. MAIN OUTCOME MEASURES: Colorectal cancer mortality and incidence, burdens, and harms over 15 years of follow-up. The certainty of the evidence was assessed using the GRADE approach. RESULTS: Over 15 years of follow-up, screening individuals aged 50-79 at 3% risk of colorectal cancer with annual FIT or single colonoscopy reduced colorectal cancer mortality by 6 per 1000 individuals. Single sigmoidoscopy and biennial FIT reduced it by 5 per 1000 individuals. Colonoscopy, sigmoidoscopy, and annual FIT reduced colorectal cancer incidence by 10, 8, and 4 per 1000 individuals, respectively. The estimated incidence reduction for biennial FIT was 1 per 1000 individuals. Serious harms were estimated to be between 3 per 1000 (biennial FIT) and 5 per 1000 individuals (colonoscopy); harms increased with older age. The absolute benefits of screening increased with increasing colorectal cancer risk, while harms were less affected by baseline risk. Results were sensitive to the setting defined by the guideline panel. Because of uncertainty associated with modelling assumptions, we applied a GRADE rating of low certainty evidence to all estimates. CONCLUSIONS: Over a 15 year period, all screening strategies may reduce colorectal cancer mortality to a similar extent. Colonoscopy and sigmoidoscopy may also reduce colorectal cancer incidence, while FIT shows a smaller incidence reduction. Harms are rare and of similar magnitude for all screening strategies.
引用
- Buskermolen M, Cenin DR, Helsingen LM, et al. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ. 2019. PMID: 31578177. doi:10.1136/bmj.l5383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。